Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Him & Hers Health Stock Doubled Options Bulls' Money
Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving.
Bulls: Bet on a Rebound for This Telehealth Stock
Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.
Hims & Hers New Growth Category Is a Huge Surprise
Is the food business the right business for Hims & Hers to be in?
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
What's Happening With HIMS Stock?
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of Eli Lilly's weight loss drug – Zepbound.
The FDA Can't Decide Whether Zepbound Is in Shortage. It's Good News for Hims & Hers Stock.
Hims & Hers markets a compounded version of a similar medicine sold by Novo Nordisk.
Hims & Hers Stock Is Down 30% This Week: Here's What Happened
Hims & Hers has given back recent gains, but don't overlook the company's massive growth.
Should You Buy Hims & Hers Stock on the Dip?
Should You Buy Hims & Hers Stock on the Dip?
Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy
Hims & Hers stands out from Teladoc by focusing on direct-to-consumer telehealth services, contrasting Teladoc's business-to-business model. This telehealth company provides personalized treatments to select conditions like weight loss, hair loss, and sexual health. A reverse DCF analysis suggests its current stock price is more than justified.
Telehealth firm Hims & Hers launches weight-loss drug shortage tracker
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's Wegovy.
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
